Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.
By Mill Chart
Last update: Mar 19, 2024
Tuesday's pre-market session: top gainers and losers
Gainers
| Ticker | Change | Comment |
|---|---|---|
| AEVA | 394.0% | AEVA TECHNOLOGIES INC (NYSE:AEVA) experienced an impressive 394.0% increase in share price, reaching $4.99 during the pre-market session on Tuesday. A press release (Aeva Technologies, Inc.’s Reverse Stock Split Becomes Effective) was released yesterday. |
| OTRK | 163.0% | ONTRAK INC's (NASDAQ:OTRK) stock price increased by 163.0% to $0.5. The stock is trading 54.76% lower than 3 months ago. |
| FUSN | 97.51% | FUSION PHARMACEUTICALS INC's (NASDAQ:FUSN) stock price increased by 97.51% to $21.02. A press release (FUSN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Fusion Pharmaceuticals Inc. Is Fair to Shareholders) was released earlier today. |
| ENVB | 49.09% | Investors witnessed a remarkable surge in ENVERIC BIOSCIENCES INC (NASDAQ:ENVB) during Tuesday's pre-market session, with the stock price rising 49.09% to $1.64. A press release (Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease) was released earlier today. |
| ZCAR | 48.31% | Investors witnessed a remarkable surge in ZOOMCAR HOLDINGS INC (NASDAQ:ZCAR) during Tuesday's pre-market session, with the stock price rising 48.31% to $1.75. The stock is trading 23.87% lower than a month ago. |
| CLDI | 25.0% | The pre-market session on Tuesday saw a significant rise in CALIDI BIOTHERAPEUTICS INC's (NYSEARCA:CLDI) shares, climbing 25.0% to $0.75. In the last 3 months the stock lost 64.07%. |
| LICY | 21.86% | LI-CYCLE HOLDINGS CORP's (NYSE:LICY) shares rose 21.86% to $1.34 during Tuesday's pre-market session. Building on yesterday's 44.09% gain, NYSE:LICY shows continued strength in today's pre-market session. Yesterday the company had a press release: Li-Cycle Provides Business Update, Following Announcement of $75 Million Investment from Glencore. |
| CERS | 21.5% | The pre-market session on Tuesday saw a significant rise in CERUS CORP's (NASDAQ:CERS) shares, climbing 21.5% to $2.26. A press release (Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients) was released earlier today. |
| CATX | 21.24% | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) experienced an impressive 21.24% increase in share price, reaching $1.17 during the pre-market session on Tuesday. In the last 3 months the stock gained 154.0%. |
| NCMI | 20.85% | During Tuesday's pre-market session, NATIONAL CINEMEDIA INC (NASDAQ:NCMI) experienced a 20.85% increase, with the stock price reaching $5.1. A press release (National CineMedia, Inc. Reports Results for Fiscal Fourth Quarter and Full Year 2023) was released yesterday. |
Our premarket gainers page will show you the full list.
Today's pre-market losers
| Ticker | Change | Comment |
|---|---|---|
| GWAV | -51.77% | The pre-market session on Tuesday witnessed a 51.77% decrease in GREENWAVE TECHNOLOGY SOLUTIO's (NASDAQ:GWAV) shares, with the stock price falling to $0.18. After a strong performance yesterday with a 23.1% gain, NASDAQ:GWAV shows signs of retracement with a 51.77% decline in today's pre-market session. |
| SEEL | -51.0% | Investors observed a 51.0% decline in SEELOS THERAPEUTICS INC's (NASDAQ:SEEL) stock price, which now stands at $0.45 during Tuesday's pre-market session. In the last 3 months the share price dropped with 41.17%. |
| PIXY | -25.29% | Despite yesterday's decline, SHIFTPIXY INC (NASDAQ:PIXY) experienced a further 25.29% decrease in share price during Tuesday's pre-market session, reaching $5.08. Following yesterday's notable 100.0% increase, NASDAQ:PIXY undergoes a 25.29% decrease in today's pre-market session, suggesting a temporary pullback. |
| MOTS | -24.45% | Today's pre-market session reveals a 24.45% decline in the stock price of MOTUS GI HOLDINGS INC (NASDAQ:MOTS), now priced at $0.48. The stock is trading 49.18% lower than 3 months ago. |
| ACXP | -23.55% | ACURX PHARMACEUTICALS INC's (NASDAQ:ACXP) stock price decreased by 23.55% to $1.98. In the last 3 months the stock lost 32.02%. |
| AFIB | -18.59% | ACUTUS MEDICAL INC's (NASDAQ:AFIB) stock price recorded a 18.59% decrease, falling to $0.21. After a strong performance yesterday with a 34.43% gain, NASDAQ:AFIB shows signs of retracement with a 18.59% decline in today's pre-market session. |
| PRSO | -17.82% | Investors observed a 17.82% decline in PERASO INC's (NASDAQ:PRSO) stock price, which now stands at $1.43 during Tuesday's pre-market session. Today NASDAQ:PRSO is releasing earnings. In the last 3 months the stock lost 84.11%. |
| WLDS | -15.69% | Tuesday's pre-market session showed a 15.69% decrease in the stock price of WEARABLE DEVICES LTD (NASDAQ:WLDS), reaching $0.49. After experiencing a 26.35% increase in yesterday's session, NASDAQ:WLDS is showing a reversal in today's pre-market session with a 15.69% decrease. Yesterday the company had a press release: Wearable Devices XR Team's Report: The Mudra Band Can Be the Neural Bridge for Apple and Meta in their Next Wave of Smart Glasses Interaction. |
| BCAN | -15.68% | The stock price of BYND CANNASOFT ENTERPRISES (NASDAQ:BCAN) is declining by 15.68%, reaching $0.02 during Tuesday's pre-market session. A press release (CannabisNewsBreaks – BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) (CSE: BYND) Announces Closing of $7M Underwritten Public Offering) was released yesterday. |
| SMR | -12.28% | NUSCALE POWER CORP's (NYSE:SMR) shares fell 12.28% to $8.86 during Tuesday's pre-market session. After a strong performance yesterday with a 28.66% gain, NYSE:SMR shows signs of retracement with a 12.28% decline in today's pre-market session. |
To see the full list of premarket losers you can use our premarket losers page.
ACURX PHARMACEUTICALS INC
NASDAQ:ACXP (4/26/2024, 7:00:00 PM)
After market: 1.93 -0.14 (-6.76%)2.07
+0.05 (+2.48%)
ACXP News
3 days ago - Acurx Pharmaceuticals, Inc.Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...
5 days ago - Acurx Pharmaceuticals, Inc.Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...
a month ago - InvestorPlaceACXP Stock Earnings: Acurx Pharmaceuticals Misses EPS for Q4 2023ACXP stock results show that Acurx Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.
a month ago - BusinessInsiderACXP Stock Earnings: Acurx Pharmaceuticals Misses EPS for Q4 2023InvestorPlace - Stock Market News, Stock Advice & Trading Tips Acurx Pharmaceuticals (NASDAQ:ACXP) just reported results for the fourth quarte...
a month ago - Acurx Pharmaceuticals, Inc.Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new...
2 months ago - Acurx Pharmaceuticals, Inc.Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...
2 months ago - AB NewswireNew to the Street TV Series on Bloomberg and Fox Business, Innovative Companies Spotlighted: ACXP, TNXP, PETV, SWISF, GEVI, CLNV2 months ago - Acurx Pharmaceuticals, Inc.Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU DevelopmentAs previously announced, planning is underway with FDA to advance ibezapolstat into international Phase 3 clinical trials for treatment of C. difficile...
3 months ago - Acurx Pharmaceuticals, Inc.Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI PatientsIn the Phase 2b trial, 100% (5 of 5) of ibezapolstat-treated patients who agreed to observation for up to three months following Clinical Cure of CDI...
3 months ago - AB NewswireAcurx Pharmaceuticals’ Phase 2b Results For Ibezapolstat Bests Standard Of Care Vancomycin To Treat C. Difficile ($ACXP)
3 months ago - Seeking AlphaAcurx stock plunges 26% amid Phase 2 data release for C. diff drug (NASDAQ:ACXP)Acurx (ACXP) stock plunged 26% in midday trading amid the release of data from a Phase 2b clinical trial for its C. diff treatment ibezapolstat. Read more here.
